辉瑞抗癌小分子组合疗法获FDA加速批准：为BRAFV600E突变结直肠癌患者 ...
虽然BRAFV600E突变转移性结直肠癌患者面临极高的未满足医疗需求，但迄今为止，针对这部分初治患者的生物标志物驱动治疗产品尚未得到批准。此次辉瑞的组合疗法获得FDA加速批准，不仅为患者带来了全新的治疗选择，也为医药行业研究和开发高效疗法提供了新的方向与动力。
Pharmabiz3 天
Pfizer’s BRAFTOVI combination regimen receives US FDA approval for treatment of ...
Pfizer’s BRAFTOVI combination regimen receives US FDA approval for treatment of metastatic colorectal cancer: New York Monday, December 23, 2024, 10:00 Hrs [IST] Pfizer Inc anno ...
Medscape5 天
Targeted Drugs in Combination With Radiotherapy for the Treatment of Solid Tumors
We have summarized in this article the current state of combination therapy of approved targeted drugs and irradiation. Since the introduction of the first targeted compounds almost (trastuzumab ...
healthandpharma6 天
FDA Approves BRAFTOVI Combination as First-Line Treatment for BRAF V600E–Mutant ...
Pfizer has confirmed it will seek potential approvals in other regions. “Today’s approval of the first combination regimen ...
Frontiers3 天
Diagnostic and therapeutic role of non-coding RNAs regulating programmed cell death in melanoma
1 Office for Doctoral Studies, Charité-Universitätsmedizin Berlin, Berlin, Germany 2 Office for Postgraduate Student Studies, Kunming Medical University, Kunming, China lncRNAs (long non-coding RNAs) ...
Armed robbery in Revesby5 天
FDA Greenlights Pfizer Combo for Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with ...
PipelineReview.com4 天
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF ...
NEW YORK, NY, USA I December 20, 2024 I Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI ® (encorafenib) in combination with cetuximab ...